1. Home
  2. FMST vs RNTX Comparison

FMST vs RNTX Comparison

Compare FMST & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foremost Lithium Resource & Technology Ltd.

FMST

Foremost Lithium Resource & Technology Ltd.

HOLD

Current Price

$1.63

Market Cap

30.5M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.53

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMST
RNTX
Founded
2005
2001
Country
Canada
United States
Employees
2
11
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.5M
30.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FMST
RNTX
Price
$1.63
$1.53
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
137.2K
119.9K
Earning Date
05-21-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$1.02
52 Week High
$5.74
$2.22

Technical Indicators

Market Signals
Indicator
FMST
RNTX
Relative Strength Index (RSI) 36.64 61.44
Support Level N/A $1.34
Resistance Level $2.52 $1.59
Average True Range (ATR) 0.15 0.18
MACD -0.01 0.03
Stochastic Oscillator 7.69 64.41

Price Performance

Historical Comparison
FMST
RNTX

About FMST Foremost Lithium Resource & Technology Ltd.

Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: